Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VYD2311

Vaccine (Peptide vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Invivyd

Phase 3 Most advanced trial

IVVD Developer

2 Registered trials

What is VYD2311?

VYD2311 is a peptide vaccine administered by intramuscular injection for COVID-19. It is studied in single-dose and multi-dose regimens.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Peptide vaccine)
Targets: SARS-CoV-2 spike protein (antigen)
Mechanism: Immune activation, directed at SARS-CoV-2 spike protein
Therapy area: Infectious disease
Developer: Invivyd, Inc. (IVVD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: PRC4J48944

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07655180	Phase 3	COVID-19	Recruiting	IVVD
NCT07298434	Phase 3	COVID-19	Active not recruiting	IVVD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19

More from Invivyd

Adintrevimab Phase 2/3 VYD222 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IVVD page.

Follow IVVD, the company behind VYD2311

See IVVD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IVVD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z